Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New anxiety pill shows promise in major trial

NCT ID NCT06809595

Symptom relief Sponsor: Definium Therapeutics US, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 3 times

Summary

This study tests an oral medication called MM120 against a placebo in 245 adults with generalized anxiety disorder. Participants take the drug or placebo for 12 weeks, and those who complete may join a 40-week follow-up where everyone gets the active drug. The goal is to see if MM120 reduces anxiety symptoms more than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

245 people

The number who actually took part.

Started

Jan 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 74 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of GAD per DSM-5 2. Male or female aged 18 to 74 3. HAM-A Total Score ≥20 Exclusion Criteria: 1. Certain psychiatric disorders (other than generalized anxiety disorder) 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine) 4. Any clinically significant unstable illness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Generalized anxiety disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

generalized anxiety disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Generalized anxiety disorder

Contacts and locations

Locations

  • 4 Medical Clinical Solutions

    London, United Kingdom

  • 4 Medical Clinical Solutions

    Manchester, United Kingdom

  • A-shine s.r.o.

    Pilsen, Czechia

  • Adams Clinical Boston

    Boston, Massachusetts, 02116, United States

  • Atlanta Center for Medical Research

    Atlanta, Georgia, 30331, United States

  • Austin Clinical Trial Partners

    Austin, Texas, 78737, United States

  • Bradenton Research Center, Inc.

    Bradenton, Florida, 34205, United States

  • CMME

    Paris, France

  • Cabinet Dr.Desbonnet : Résidence Saint Michel

    Douai, France

  • Central Institute of Mental Health

    Mannheim, Germany

  • Centre Hospitalier du Rouvray

    Sotteville-lès-Rouen, France

  • Centrum Badan Klinicznych PI-House sp. z o.o.

    Gdansk, Poland

  • Clerkenwell Health

    London, United Kingdom

  • Clerkenwell Health - Baker Street

    London, United Kingdom

  • Clinical Neuroscience Solutions, Inc

    Orlando, Florida, 32801, United States

  • Core Clinical Research

    Everett, Washington, 98201, United States

  • Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, St. Nicholas Hospital

    Gosforth, United Kingdom

  • Department of Affective and Psychotic Disorders, Central Teaching Hospital, Medical University of Lodz

    Lodz, Poland

  • Department of Psychiatry and Psychotherapy Campus Charité Mitte Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Department of Psychiatry, UCK

    Gdansk, Poland

  • GHU Paris Psychiatrie et Neurosciences

    Paris, France

  • Hôpital Conception, CIC Centre, bat néphrologie 3eme étage

    Marseille, France

  • Institut Neuropsychiatricke Pece (INEP)

    Prague, Czechia

  • Klinik für Psychiatrie und Psychotherapie, Abt: Allgemeine Psychiatrie und Psychotherapie

    Tübingen, Germany

  • Neuro-Behavioral Clinical Research, Inc.

    North Canton, Ohio, 44720, United States

  • Neuroclin Glasgow

    Glasgow, United Kingdom

  • OVID Clinic Berlin

    Berlin, Germany

  • Preferred Research Partners, Inc.

    Little Rock, Arkansas, 72211, United States

  • Princeton Medical Institute

    Princeton, New Jersey, 08540, United States

  • Psychedelic Science Institute

    Los Angeles, California, 90004, United States

  • Psyon s.r.o.

    Prague, Czechia

  • Sheppard Pratt Health System

    Towson, Maryland, 21204, United States

  • South London and Maudsley NHS Foundation Trust of The Maudsley Hospital

    London, United Kingdom

  • St George's Community Health Centre

    Sheffield, United Kingdom

  • University of Cincinnati Psychiatry- Anxiety Disorders Research Program

    Cincinnati, Ohio, 45219, United States

  • West Los Angeles VA Medical Center

    Los Angeles, California, 90073, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.